Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

(2016) D. H. Charych et al.   CLINICAL CANCER RESEARCH

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1

(2015) Amer Assal et al.   Immunotherapy

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

(2015) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Formulation and Stability of Cytokine Therapeutics

(2015) Tiina Lipiäinen et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Abstract A6: RNAseq and immune profiling analysis of syngeneic mouse models treated with immune checkpoint inhibitors enable biomarker discovery and model selection for cancer immunotherapy

(2015) Lan Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Release the Hounds! Activating the T-Cell Response to Cancer

(2015) Mario Sznol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

(2015) Isabelle Le Mercier et al.   Frontiers in Immunology

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

(2014) Roxanne Payne et al.   Journal for ImmunoTherapy of Cancer

Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics

(2013) Kalet León et al.   Frontiers in Immunology

Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies

(2012) K. Garcia-Martinez et al.   INTERNATIONAL IMMUNOLOGY

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged Interleukin-2Rα Expression on Virus-Specific CD8+ T Cells Favors Terminal-Effector Differentiation In Vivo

(2010) Vandana Kalia et al.   IMMUNITY

Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response

(2010) Ofer Feinerman et al.   Molecular Systems Biology

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor   subunit CD25

(2010) S. Letourneau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments

(2010) D. Busse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics

(2008) C.Simone Fishburn   JOURNAL OF PHARMACEUTICAL SCIENCES